Bifidobacterium longum subsp. infantis CECT7210

Bifidobacterium longum subsp. infantis CECT7210 is a clinically studied probiotic strain that colonizes the infant gut and reduces diarrhea incidence through competitive exclusion of pathogens and modulation of intestinal barrier integrity. Its primary mechanism involves producing short-chain fatty acids and binding to intestinal epithelial cells to block rotavirus attachment and replication.

Origin & History

Bifidobacterium longum subsp. infantis CECT7210 (marketed as B. infantis IM-1®) is a probiotic bacterial strain isolated from the feces of breastfed infants and deposited in the Spanish Type Culture Collection. This gram-positive, anaerobic bacterium naturally occurs in the human gastrointestinal microbiota and was selected for its capacity to inhibit rotavirus replication and protect against gastrointestinal pathogens.

Historical & Cultural Context

The research does not document any traditional medicine applications for this specific strain. Bifidobacterium longum subsp. infantis naturally colonizes the infant gut, particularly in breastfed babies, but formal historical use is not documented.

Health Benefits

• Reduces diarrhea episodes in infants - clinical trial showed reduction from 0.29 to 0.05 events per infant over 12 weeks (moderate evidence)
• Provides protection against rotavirus infection - demonstrated 48.5% protection in cell lines and delayed viral shedding in mouse models (preliminary evidence)
• Inhibits intestinal pathogens - displaces Cronobacter sakazakii and Salmonella enterica while preventing their adhesion to intestinal cells (preliminary evidence)
• Stimulates intestinal immune response - increases villous intraepithelial lymphocytes in animal models (preliminary evidence)
• Improves intestinal recovery - faster recovery with improved intestinal villous:crypt ratio in infected animals (preliminary evidence)

How It Works

B. longum subsp. infantis CECT7210 adheres to intestinal epithelial cells via surface-layer proteins and exopolysaccharides, competitively displacing enteric pathogens including rotavirus from mucosal binding sites. The strain produces short-chain fatty acids (primarily acetate and lactate) that lower luminal pH, inhibiting pathogen proliferation and reinforcing tight-junction proteins such as claudin-1 and occludin to reduce paracellular permeability. Additionally, it modulates innate immune signaling through Toll-like receptor 2 and 4 pathways, promoting regulatory cytokine profiles that dampen pro-inflammatory responses during enteric infection.

Scientific Research

A randomized controlled trial in 190 infants under 3 months demonstrated that formula supplemented with B. infantis CECT7210 reduced diarrhea episodes over 12 weeks, with statistical significance reached at 8 weeks (P=0.047). Preclinical studies in BALB/c mice showed significant protection against rotavirus infection with reduced viral shedding and antigen concentration. The research base is limited to infant populations with no published PMIDs available in the provided sources.

Clinical Summary

A randomized controlled trial demonstrated that infants receiving B. longum subsp. infantis CECT7210 experienced a reduction in diarrhea events from 0.29 to 0.05 episodes per infant over a 12-week supplementation period, representing an approximately 83% reduction. In vitro studies on MA-104 cell lines showed 48.5% protection against rotavirus infection, and mouse model experiments documented delayed viral shedding following oral challenge. Evidence for anti-diarrheal effects is rated moderate based on the controlled trial design, while rotavirus-specific protection remains at a preliminary level due to reliance on preclinical models. No large-scale phase III trials have yet confirmed rotavirus outcomes in human infants, warranting cautious interpretation of the antiviral data.

Nutritional Profile

Bifidobacterium longum subsp. infantis CECT7210 is a probiotic microorganism; its nutritional contribution is characterized by its cellular biomass and metabolic byproducts rather than classical macronutrient content. Protein content of bacterial cells constitutes approximately 50-60% of dry cell weight, primarily structural and enzymatic proteins including glycosidases and sialidases that facilitate human milk oligosaccharide (HMO) metabolism. Lipid content accounts for roughly 15-20% of dry cell weight, mainly membrane phospholipids and glycolipids. Carbohydrate content (as cell wall polysaccharides, including peptidoglycan and exopolysaccharides) represents approximately 10-20% of dry cell weight. Key bioactive compounds produced include: short-chain fatty acids (SCFAs), predominantly acetate (primary fermentation end-product from HMO catabolism, concentrations in gut range 20-100 mM depending on substrate availability), and lactate. The strain produces B-group vitamins including folate (B9) and riboflavin (B2) as metabolic byproducts at trace levels. It expresses a unique complement of HMO-utilization genes enabling catabolism of lacto-N-tetraose, lacto-N-neotetraose, and sialylated oligosaccharides. Surface-layer proteins (SlpA) and sortase-dependent pili facilitate colonization and immune modulation. No significant dietary minerals, fiber, or fat-soluble vitamins are contributed directly. Bioavailability note: beneficial effects are mediated through live cell viability (typically delivered at 10^8-10^9 CFU per dose); metabolites and cell surface components are bioactive locally within the gut lumen and mucosa rather than through systemic absorption.

Preparation & Dosage

The strain has been clinically studied only in infant formula supplementation over 12-week periods in babies under 3 months of age. Specific CFU (colony-forming units) per dose are not provided in available research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other Bifidobacterium strains, Lactobacillus rhamnosus, Saccharomyces boulardii, Prebiotics (FOS/GOS), Vitamin D3

Safety & Interactions

B. longum subsp. infantis CECT7210 is generally considered safe for healthy term infants and has not produced serious adverse events in published clinical trials; mild transient gastrointestinal symptoms such as bloating or increased flatulence are theoretically possible as with any probiotic. Immunocompromised infants, preterm neonates with very low birth weight, or those with central venous catheters should use probiotic strains only under direct medical supervision due to rare risk of bacteremia reported with Bifidobacterium species in vulnerable populations. No clinically significant drug interactions have been documented, though concurrent antibiotic use will reduce strain viability and efficacy, making post-antibiotic timing or dose separation advisable. Pregnancy and lactation safety data are not applicable given the intended infant population, and adult use has not been formally studied for this specific strain.